|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...56575859606162636465666768» |
- | figitumumab (CP-751,871) / Novartis
New P1 trial: CP-751,871 Treatment For Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 16, 2012
P1, N=47, Completed, Sponsor: Pfizer
- bortezomib / Generic mfg., dexamethasone / Generic mfg.
Enrollment closed: Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT (clinicaltrials.gov) - Feb 16, 2012
P2/3, N=40, Active, not recruiting, Sponsor: Tampere University Hospital
Recruiting --> Active, not recruiting
- Enrollment closed: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Feb 15, 2012
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P2 trial: High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 14, 2012
P2, N=1, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
- | Trial completion: Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=32, Completed, Sponsor: Terumo BCT
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Corifact (human coagulation factor XIII) / CSL Behring
Trial completion: An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency (clinicaltrials.gov) - Feb 13, 2012
P3, N=61, Completed, Sponsor: CSL Behring
Recruiting --> Completed Active, not recruiting --> Completed
- ||| lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial initiation date, Combination therapy: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (clinicaltrials.gov) - Feb 13, 2012
P1/2, N=90, Recruiting, Sponsor: UMC Utrecht
Active, not recruiting --> Completed Initiation date: May 2011 --> Aug 2011
- warfarin / Generic mfg.
Biomarker, Enrollment change: PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care (clinicaltrials.gov) - Feb 13, 2012
P4, N=0, Withdrawn, Sponsor: University of Florida
Initiation date: May 2011 --> Aug 2011 N=500 --> 0
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 13, 2012
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- |||| lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open, Combination therapy: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (clinicaltrials.gov) - Feb 13, 2012
P1/2, N=90, Recruiting, Sponsor: UMC Utrecht
N=500 --> 0 Not yet recruiting --> Recruiting
- | bortezomib / Generic mfg., bendamustine / Generic mfg.
Enrollment change: Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2012
P1/2, N=40, Completed, Sponsor: Cephalon
Not yet recruiting --> Recruiting N=50 --> 40
- | bortezomib / Generic mfg., bendamustine / Generic mfg.
Trial completion: Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2012
P1/2, N=40, Completed, Sponsor: Cephalon
N=50 --> 40 Active, not recruiting --> Completed
- | Sylvant (siltuximab) / Jazz
New P1/2 trial: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=11, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- | tasisulam (LY573636) / Eli Lilly
Trial completion: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 9, 2012
P1, N=45, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- RG7444 / Roche
Trial initiation date: A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma (clinicaltrials.gov) - Feb 6, 2012
P1, N=14, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Initiation date: May 2010 --> Nov 2010
- Sylvant (siltuximab) / Jazz
Enrollment change, Combination therapy: A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 6, 2012
P3, N=0, Withdrawn, Sponsor: Centocor, Inc.
Initiation date: May 2010 --> Nov 2010 N=500 --> 0
- | bortezomib / Generic mfg., melphalan / Generic mfg., carfilzomib / Generic mfg.
Clinical: Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments (clinicaltrials.gov) - Feb 5, 2012
P1/2, N=45, Active, not recruiting, Sponsor: Oncotherapeutics
N=500 --> 0 N=30 --> 45
- || Enrollment closed, HEOR: Quality of Life Study of Helixate NexGen (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=150, Active, not recruiting, Sponsor: CSL Behring
N=30 --> 45 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Combination therapy: Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P=N/A, N=30, Completed, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: UMCC 2004.047: Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma (clinicaltrials.gov) - Feb 4, 2012
P2, N=40, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Empliciti (elotuzumab) / AbbVie, BMS
Enrollment open: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 2, 2012
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (clinicaltrials.gov) - Feb 1, 2012
P3, N=240, Recruiting, Sponsor: Shandong University
- Empliciti (elotuzumab) / AbbVie, BMS
Enrollment closed, Combination therapy: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (clinicaltrials.gov) - Feb 1, 2012
P1, N=20, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | bortezomib / Generic mfg.
New P4 trial: Retrospective Survey of Re-treatment With Bortezomib (clinicaltrials.gov) - Jan 31, 2012
P4, N=35, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
- ||||| Zelboraf (vemurafenib) / Roche
New P2 trial: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Jan 31, 2012
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
- Signifor LAR (pasireotide long acting release) / Recordati
Trial withdrawal, Combination therapy: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- ||||| Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring
Trial initiation date: BE1116_3003: An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX (clinicaltrials.gov) - Jan 30, 2012
P3, N=176, Completed, Sponsor: CSL Behring
Not yet recruiting --> Withdrawn Initiation date: Oct 2008 --> Feb 2009
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Combination therapy: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Initiation date: Oct 2008 --> Feb 2009 N=40 --> 0
- New P1 trial: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Jan 30, 2012
P1, N=18, Recruiting, Sponsor: Robert Lowsky
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: A Standardized Nursing Intervention Protocol for HCT Patients (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=282, Completed, Sponsor: City of Hope Medical Center
N=40 --> 0 Active, not recruiting --> Completed
- |||||||||| Promacta (eltrombopag) / Novartis
New P3 trial: PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) - Jan 26, 2012
P3, N=92, Completed, Sponsor: GlaxoSmithKline
- olaptesed pegol (NOX-A12) / TME Pharma
New P2a trial, Combination therapy: NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2012
P2a, N=29, Active, not recruiting, Sponsor: Noxxon Pharma AG
- New P2 trial: Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM (clinicaltrials.gov) - Jan 26, 2012
P2, N=30, Recruiting, Sponsor: Azienda Ospedaliera di Bolzano
- Trial completion, Pre-transplantation, Post-transplantation: Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY (clinicaltrials.gov) - Jan 26, 2012
P1/2, N=95, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Promacta (eltrombopag) / Novartis
Enrollment change: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Jan 25, 2012
P3, N=302, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=400 --> 302
- ||| gandotinib (LY 2784544) / Eli Lilly
New P1 trial: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - Jan 25, 2012
P1, N=100, Recruiting, Sponsor: Eli Lilly and Company
- ||| afuresertib (LAE002) / Laekna Therap
Enrollment open, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jan 25, 2012
P1, N=90, Recruiting, Sponsor: GlaxoSmithKline
N=400 --> 302 Not yet recruiting --> Recruiting
- | Idelvion (albutrepenonacog alfa) / CSL Behring
Trial completion: Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B (clinicaltrials.gov) - Jan 25, 2012
P1, N=25, Completed, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=2211, Completed, Sponsor: University of Vermont
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=4, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=27 --> 4
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Jan 24, 2012
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=27 --> 4 N=60 --> 92
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
New P2 trial, Combination therapy: Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2012
P2, N=30, Recruiting, Sponsor: University of Southern California
- Enrollment open: METRO: Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2012
P=N/A, N=70, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
N=60 --> 92 Not yet recruiting --> Recruiting
- Enrollment change: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=31, Active, not recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting N=45 --> 31
- pirfenidone / Generic mfg.
Enrollment closed: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Jan 23, 2012
P2, N=35, Active, not recruiting, Sponsor: William Gahl
N=45 --> 31 Terminated --> Active, not recruiting
- | Rytelo (imetelstat) / Geron
Trial completion, Combination therapy: Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1, N=40, Completed, Sponsor: Geron Corporation
Terminated --> Active, not recruiting Active, not recruiting --> Completed
- | Rytelo (imetelstat) / Geron
Trial completion: Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1, N=20, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open, Surgery: Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. (clinicaltrials.gov) - Jan 22, 2012
P4, N=60, Recruiting, Sponsor: University Children's Hospital, Zurich
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P3 trial: Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Jan 22, 2012
P3, N=440, Recruiting, Sponsor: King Faisal Specialist Hospital & Research Center
- | Jakafi (ruxolitinib) / Incyte
Trial completion: A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 19, 2012
P2, N=13, Completed, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed